IMMvention Therapeutix

IMMvention Therapeutics is a pre-clinical stage company developing oral therapeutics for neuroinflammatory diseases with high unmet need, and cardiometabolic disease. IMMvention's lead drug cadidate is an oral inhibitor focused on a novel target in the Nrf2 pathway.